---
title: "How Labcorp's FDA-Cleared Blood Test for Alzheimer’s Has Changed Its Investment Story (LH)"
description: "Labcorp has launched the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood test for Alzheimer's, enhancing its investment narrative by supporting early diagnosis and increasing co"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255314068.md"
published_at: "2025-08-30T13:35:30.000Z"
---

# How Labcorp's FDA-Cleared Blood Test for Alzheimer’s Has Changed Its Investment Story (LH)

> Labcorp has launched the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood test for Alzheimer's, enhancing its investment narrative by supporting early diagnosis and increasing competitive positioning. Despite this innovation, Labcorp faces significant short-term risks from competitive pressures in diagnostics. The company forecasts $15.6 billion in revenue and $1.3 billion in earnings by 2028, with a fair value estimate of $293.76, indicating a 6% upside. Investors should consider market risks and diverse fair value estimates from the community, ranging from $200 to $447.95.

-   Labcorp recently announced the nationwide availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood-based in-vitro diagnostic test to support Alzheimer's disease diagnosis through early detection of amyloid plaques in adults showing cognitive decline.
-   This launch offers a less invasive and potentially more accessible alternative to current diagnostic methods, arriving as new clinical guidelines support wider use of blood-based biomarkers for Alzheimer’s disease assessment.
-   We'll examine how Labcorp’s introduction of this FDA-cleared Alzheimer's test may influence its investment outlook and growth narrative.

The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

## Labcorp Holdings Investment Narrative Recap

Labcorp shareholders generally look for growth powered by innovation in diagnostics, operational scale, and earnings strength. The recent launch of the FDA-cleared Lumipulse® pTau-217/Beta Amyloid 42 blood test for Alzheimer’s offers incremental upside to Labcorp’s growth story by supporting volume and differentiation, enhancing its competitive position as blood-based biomarkers gain acceptance. However, this development does not eliminate competitive pressures in diagnostics, which remain the most significant short-term risk to the business as pricing and contract renewals can affect revenue and margins.

Among recent announcements, the July 2025 release of “Test Finder,” a generative AI tool to streamline lab test selection for providers, stands out as highly relevant. Combining the new Alzheimer’s test with advanced AI tools could help Labcorp capture more test volume and reinforce its reputation for leadership in innovation, supporting the view that product pipeline strength is the key catalyst for sustained earnings growth.

By contrast, investors should be aware that even with new FDA-cleared tests, Labcorp still faces market risk if competitors ...

Read the full narrative on Labcorp Holdings (it's free!)

Labcorp Holdings' outlook forecasts $15.6 billion in revenue and $1.3 billion in earnings by 2028. This is based on a 5.1% annual revenue growth rate and an earnings increase of $536.6 million from the current $763.4 million.

Uncover how Labcorp Holdings' forecasts yield a $293.76 fair value, a 6% upside to its current price.

## Exploring Other Perspectives

Fair value estimates from three Simply Wall St Community members span US$200 to US$447.95, underscoring diverse potential for the shares. Consider how competitive pressures in diagnostics may influence these varied forecasts and the company's future performance.

Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth 28% less than the current price!

## Build Your Own Labcorp Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

-   A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
-   Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.

## Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

-   AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
-   We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
-   This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

*This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.*

### Related Stocks

- [LH.US - Labcorp](https://longbridge.com/en/quote/LH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 内部人士出售：实验美控（NYSE:LH）执行副总裁出售 87 股股票 | Labcorp Holdings Inc. 的执行副总裁 Jonathan Meltzer 出售了 87 股股票，平均价格为 290.42 美元，总计 25,266.54 美元，减少了 3.03% 的持股比例。出售后，他持有 2,782 股 | [Link](https://longbridge.com/en/news/275940506.md) |
| Candriam S.C.A. 减少了在实验美控控股公司（Labcorp Holdings Inc.）的股票头寸 $LH | Candriam S.C.A. 在第三季度减少了对 Labcorp Holdings Inc. (NYSE:LH) 的持股比例，下降了 39.3%，目前持有 46,666 股，价值约 1340 万美元。其他机构投资者也进行了与 Labcor | [Link](https://longbridge.com/en/news/275582275.md) |
| 实验美控完成了对帝国城市实验室资产的收购 | 实验美控已完成对帝国城市实验室部分资产的收购，包括患者服务中心，以增强纽约市地区的实验室检测可及性。此次合作旨在通过将帝国城市实验室的本地服务与实验美控的资源和数字工具相结合，改善患者护理并扩展检测选项。两家机构的领导人强调了他们对高质量护 | [Link](https://longbridge.com/en/news/275364400.md) |
| 实验美控任命 John H. Sampson 进入董事会 | Labcorp Holdings Inc. 宣布任命 Dr. John H. Sampson, M.D., Ph.D., MHSc, MBA 为其董事会成员。Sampson 博士还将担任质量与合规委员会的成员。他目前是科罗拉多大学安舒茨医学 | [Link](https://longbridge.com/en/news/275325049.md) |
| 实验美控公司任命新董事会成员 | Labcorp Holdings Inc. 已任命约翰·H·桑普森博士为其董事会成员，任命将于 2026 年 2 月 9 日生效。桑普森博士是科罗拉多大学安舒茨医学院的健康事务副校长和院长，同时还将加入质量与合规委员会。关于他被任命的原因尚 | [Link](https://longbridge.com/en/news/275326615.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
